Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 8, Issue 9, Pages 1057-1069Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.2012.693480
Keywords
cancer; mathematical models; Model Based Drug Development (MBDD); oncology drug development; pharmacokinetic-pharmacodynamic models
Funding
- Clinical Pharmacology Department of Janssen Research and Development LLC.
Ask authors/readers for more resources
Introduction: Approaches aiming to model the time course of tumor growth and tumor growth inhibition following a therapeutic intervention have recently been proposed for supporting decision making in oncology drug development. When considered in a comprehensive model-based approach, tumor growth can be included in the cascade of quantitative and causally related markers that lead to the prediction of survival, the final clinical response. Areas covered: The authors examine articles dealing with the modeling of tumor growth and tumor growth inhibition in both preclinical and clinical settings. In addition, the authors review models describing how pharmacological markers can be used to predict tumor growth and models describing how tumor growth can be linked to survival endpoints. Expert opinion: Approaches and success stories of application of model-based drug development centered on tumor growth modeling are growing. It is also apparent that these approaches can answer practical questions on drug development more effectively than that in the past. For modeling purposes, some improvements are still needed related to study design and data quality. Further efforts are needed to encourage the mind shift from a simple description of data to the prediction of untested conditions that modeling approaches allow.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available